Literature DB >> 35368344

Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease.

Taro Akihisa1, Shun Manabe1, Hiroshi Kataoka1, Shiho Makabe1, Rie Yoshida1, Yusuke Ushio1, Kentaro Watanabe1, Masayo Sato1, Ken Tsuchiya2, Toshio Mochizuki1, Kosaku Nitta1.   

Abstract

This is the first report to describe dose dependency in the effects of tolvaptan treatment for autosomal dominant polycystic kidney disease.The weight-adjusted average daily dose of tolvaptan was found to be a factor that significantly affected the change in eGFR.If a patient shows tolerance, increasing the tolvaptan dose to the maximum should be considered.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; cystic kidney disease; dose-dependent; estimated glomerular filtration rate; prognostic factor; renal prognosis; tolvaptan; total kidney volume

Mesh：

Substances：

Year:  2021        PMID： 35368344      PMCID： PMC8786106          DOI： 10.34067/KID.0007342020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


  10 in total

1.  The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Authors:  Satoru Muto; Haruna Kawano; Eiji Higashihara; Ichiei Narita; Yoshifumi Ubara; Takayuki Matsuzaki; John Ouyang; Vicente E Torres; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2015-02-07       Impact factor: 2.801

2.  Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Authors:  Gail A Reif; Tamio Yamaguchi; Emily Nivens; Hiroyuki Fujiki; Cibele S Pinto; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-03

3.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

4.  The number of subjects per variable required in linear regression analyses.

Authors:  Peter C Austin; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2015-01-22       Impact factor: 6.437

5.  Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.

Authors:  Seong Ryul Kim; Tomoko Hasunuma; Osamu Sato; Tadashi Okada; Mitsuhiro Kondo; Junichi Azuma
Journal:  Cardiovasc Drugs Ther       Date:  2011-12       Impact factor: 3.727

6.  Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Authors:  Miki Aihara; Hiroyuki Fujiki; Hiroshi Mizuguchi; Katsuji Hattori; Koji Ohmoto; Makoto Ishikawa; Keisuke Nagano; Yoshitaka Yamamura
Journal:  J Pharmacol Exp Ther       Date:  2014-02-25       Impact factor: 4.030

7.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

9.  Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Authors:  Susan E Shoaf; Arlene B Chapman; Vicente E Torres; John Ouyang; Frank S Czerwiec
Journal:  J Clin Pharmacol       Date:  2017-02-20       Impact factor: 3.126

10.  Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

Authors:  Olivier Devuyst; Arlene B Chapman; Susan E Shoaf; Frank S Czerwiec; Jaime D Blais
Journal:  Kidney Int Rep       Date:  2017-07-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.